Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia

Giving chemotherapy drugs, such as R115777, isotretinoin, cytarabine, and fludarabine, before a donor bone marrow transplant or an umbilical cord transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. This phase II trial is studying how well giving combination chemotherapy together with donor bone marrow or umbilical cord blood transplant works in treating children with newly diagnosed juvenile myelomonocytic leukemia

Study Overview

• Status: Completed
• Conditions: Juvenile Myelomonocytic Leukemia
• Intervention / Treatment: Other: laboratory biomarker analysis; Drug: fludarabine phosphate; Drug: tipifarnib; Drug: cyclophosphamide; Drug: cytarabine; Drug: isotretinoin; Biological: anti-thymocyte globulin; Radiation: radiation therapy; Procedure: allogeneic bone marrow transplantation; Procedure: double-unit umbilical cord blood transplantation; Procedure: umbilical cord blood transplantation

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the response rate of children with newly diagnosed juvenile myelomonocytic leukemia treated with R115777, isotretinoin, cytarabine, and fludarabine followed by allogeneic bone marrow or umbilical cord blood transplantation.

II. Determine the safety and toxicity of this regimen in these patients. III. Determine the tolerability of this regimen in these patients. IV. Determine the rate of 2-year event-free survival of patients treated with this regimen.

V. Determine whether prognostic subsets of these patients can be identified based on expression of clinical, genetic (NFI, monosomy 7, RAS gene), or hematopoietic characteristics.

OUTLINE: This is a multicenter study.

Patients may choose to receive upfront window induction therapy with oral R115777 twice daily on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.

Patients with progressive disease or stable disease with unacceptable hematopoietic recovery after 1 course proceed to induction chemotherapy. (R11577 portion of the study closed to accrual as of 08/2005)

All patients receive induction chemotherapy comprising oral isotretinoin once daily beginning on day 1 and fludarabine IV over 30 minutes and cytarabine IV over 4 hours on days 1-5. Treatment with fludarabine and cytarabine repeats every 28 days for 2 courses. Treatment with isotretinoin continues until allogeneic bone marrow or umbilical cord blood transplantation. Patients with progressive disease after 1 course proceed to transplantation.

After completion of isotretinoin, patients receive a preparative regimen comprising total body irradiation twice daily on days -7 to -4, cyclophosphamide IV over 2 hours on days -3 and -2, and anti-thymocyte globulin IV over 4-6 hours every 12 hours on days -3 to -1. Patients undergo allogeneic bone marrow or umbilical cord blood transplantation on day 0. Patients receive oral isotretinoin daily beginning on approximately day 60 and continuing for 1 year.

Patients are followed every 6 months for 5 years and then annually thereafter.

PROJECTED ACCRUAL: A maximum of 100 patients (18-46 receiving R115777 with induction chemotherapy [R11577 portion of the study closed to accrual as of 08/2005] and 27-54 receiving induction chemotherapy only) will be accrued for this study within 3.2 years.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Arcadia, California, United States, 91006-3776
      • Children's Oncology Group

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 16 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Newly diagnosed, previously untreated juvenile myelomonocytic leukemia

• Presenting with all of the following:

  • Absence of t(9;22) or bcr/abl by PCR
  • Absolute monocyte count greater than 1,000/mm^3
  • Less than 20% bone marrow blasts

• Presenting with at least 2 of the following:

  • Elevated F hemoglobin
  • Myeloid precursors in peripheral blood
  • WBC greater than 10,000/mm^3
  • Sargramostim (GM-CSF) hypersensitivity
• See Disease Characteristics
• Bilirubin no greater than 2.0 mg/dL
• ALT no greater than 3 times normal
• Creatinine no greater than 2 times normal
• No concurrent sargramostim (GM-CSF)
• No concurrent proton pump inhibitors

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (tipifarnib, bone marrow/umbilical cord transplant); See detailed description.

Other: laboratory biomarker analysis; Correlative studies; Drug: fludarabine phosphate; Given IV; Other Names: 2-F-ara-AMP; Beneflur; Fludara; Drug: tipifarnib; Given orally; Other Names: R115777; Zarnestra; Drug: cyclophosphamide; Given IV; Other Names: Cytoxan; Endoxan; CPM; CTX; Endoxana; Drug: cytarabine; Given IV; Other Names: Cytosar-U; cytosine arabinoside; ARA-C; arabinofuranosylcytosine; arabinosylcytosine; Drug: isotretinoin; Given orally; Other Names: 13-CRA; Amnesteem; Cistane; Claravis; Sotret; Biological: anti-thymocyte globulin; Given IV; Other Names: ATGAM; ATG; Thymoglobulin; lymphocyte immune globulin; Radiation: radiation therapy; Undergo total body irradiation; Other Names: irradiation; radiotherapy; therapy, radiation; Procedure: allogeneic bone marrow transplantation; Undergo allogeneic bone marrow transplant; Other Names: bone marrow therapy, allogeneic; bone marrow therapy, allogenic; transplantation, allogeneic bone marrow; transplantation, allogenic bone marrow; Procedure: double-unit umbilical cord blood transplantation; Procedure: umbilical cord blood transplantation; Undergo allogeneic cord blood transplant; Other Names: UCB transplantation; cord blood transplantation; transplantation, umbilical cord blood

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response rate (CR or PR)	The response rates in the up-front window with respect to whether or not patients had vas activating mutations will also be estimated by proportions.	Up to 6 years
Duration of response	Will be estimated by Kaplan-Meier method.	Up to 6 years
Progression-free survival	Will be estimated by Kaplan-Meier method.	2 years
Evaluation of prognostic importance of genetic marker	Logrank test and Cox proportional hazards model will be applied.	Up to 6 years
Grade 3 or greater toxicities assessed using CTC version 2.0		Up to 6 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival of patients receiving the window vs. not		Up to 6 years
Response status on end of course reports (pre vs.post)	Signed-rank comparison of components of therapy will be done.	Up to 6 years

Collaborators and Investigators

• Sponsor: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Robert Castleberry, Children's Oncology Group

Study record dates

Study Major Dates

• Study Start: June 1, 2001
• Primary Completion (Actual): October 1, 2007

Study Registration Dates

• First Submitted: October 11, 2001
• First Submitted That Met QC Criteria: January 26, 2003
• First Posted (Estimate): January 27, 2003

Study Record Updates

• Last Update Posted (Estimate): April 11, 2013
• Last Update Submitted That Met QC Criteria: April 10, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Bone Marrow Diseases; Hematologic Diseases; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myeloid; Leukemia; Leukemia, Myelomonocytic, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Juvenile; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Dermatologic Agents; Cyclophosphamide; Immunoglobulins; Fludarabine; Fludarabine phosphate; Cytarabine; Tipifarnib; Thymoglobulin; Antilymphocyte Serum; Isotretinoin
• Other Study ID Numbers: NCI-2012-01861; U10CA098543 (U.S. NIH Grant/Contract); AAML0122; CDR0000068788 (Registry Identifier: PDQ (Physician Data Query))